Inhibition of cyclooxygenase-1 does not reduce mortality in post-ischemic stroke rats

摘要: Abstract Background Ischemic stroke is one of the leading causes mortality and morbidity. The currently available non-invasive therapeutic options are not sufficiently efficacious. Post-ischemic brain characterized by a prominent inflammatory response. Little known about involvement cyclooxygenase (COX)-1 in pathophysiology ischemic stroke. Objective This study was undertaken to examine effects highly selective COX-1 inhibitor – mofezolac on clinical outcomes markers post-stroke rats. Methods Stroke induced subjecting rats permanent middle cerebral artery occlusion (MCAO). Control underwent sham surgery. Rats were treated with (50 mg/kg, intraperitoneally [ip]) once daily for 14 days. animals vehicle. Body temperature (BT), neurological score (NS) cumulative monitored at different time points. At end experiment, euthanized three regions (hypothalamus, hippocampus frontal cortex) extracted. Levels interleukin (IL)-6, prostaglandin (PG)E2 tumor necrosis factor (TNF)-α these determined ELISA kits. Results BT, NS all significantly higher post-MCAO than sham-operated rats, irrespective treatment given. rate did differ between mofezolac-treated vehicle-treated animals. BT lower as compared Mofezolac alter any time-point. Cumulative 14-day non-significantly (48 % vs. 21 %, respectively; P =  0.184). Mostly, IL-6 TNF-α levels affected treatment. In contrast, decreased PGE2 rats’ brains. Conclusion Overall, results suggest that chronic reduce morbidity or